Perrigo PT Raised to $160.00 (PRGO)
Analysts at JPMorgan Chase & Co. increased their price target on shares of Perrigo (NASDAQ:PRGO) from $150.00 to $160.00 in a research report issued to clients and investors on Friday, StockRatingsNetwork reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s target price would suggest a potential upside of 12.38% from the company’s current price.
A number of other firms have also recently commented on PRGO. Analysts at Zacks reiterated a “neutral” rating on shares of Perrigo in a research note to investors on Friday. They now have a $145.00 price target on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Perrigo to $146.00 in a research note to investors on Friday. They now have a “market perform” rating on the stock. Finally, analysts at Argus initiated coverage on shares of Perrigo in a research note to investors on Monday, October 21st. They set a “buy” rating and a $152.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $134.62.
Perrigo (NASDAQ:PRGO) traded up 3.26% during mid-day trading on Friday, hitting $142.38. The stock had a trading volume of 2,538,096 shares. Perrigo has a 52-week low of $98.79 and a 52-week high of $142.58. The stock’s 50-day moving average is $128.3 and its 200-day moving average is $123.3. The company has a market cap of $13.400 billion and a price-to-earnings ratio of 29.46.
Perrigo (NASDAQ:PRGO) last posted its quarterly earnings results on Thursday, October 31st. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.12. The company had revenue of $933.00 million for the quarter, compared to the consensus estimate of $900.10 million. During the same quarter last year, the company posted $1.27 earnings per share. Perrigo’s revenue was up 21.3% compared to the same quarter last year. Analysts expect that Perrigo will post $6.55 EPS for the current fiscal year.
Perrigo Company is a global healthcare supplier that develops, manufactures and distributes over-the-counter (NASDAQ:PRGO) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products and active pharmaceutical ingredients (API).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.